The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Validation of the Immunoscore (IM) as a prognostic marker in stage I/II/III colon cancer: Results of a worldwide consortium-based analysis of 1,336 patients.
 
Jerome Galon
Stock and Other Ownership Interests - HalioDx
Honoraria - AstraZeneca; Bristol-Myers Squibb; Compugen; Definiens; HalioDx; NanoString Technologies; Novartis
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Compugen; Definiens; HalioDx; NanoString Technologies; Novartis
Research Funding - iOMEDICO (Inst); Janssen (Inst); MedImmune (Inst)
Patents, Royalties, Other Intellectual Property - INSERM
 
Bernhard Mlecnik
No Relationships to Disclose
 
Florence Marliot
Patents, Royalties, Other Intellectual Property - INSERM
 
Fang-Shu Ou
No Relationships to Disclose
 
Carlo Bruno Bifulco
Employment - Providence Health and Services
Stock and Other Ownership Interests - PrimeVax
Consulting or Advisory Role - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb (Inst)
Patents, Royalties, Other Intellectual Property - Providence (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Ventana Medical Systems
 
Alessandro Lugli
Honoraria - 3-D-Histech
Travel, Accommodations, Expenses - 3-D-Histech
 
Inti Zlobec
No Relationships to Disclose
 
Tilman T. Rau
No Relationships to Disclose
 
Arndt Hartmann
Honoraria - AstraZeneca; MSD; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; MSD; Roche/Genentech
Research Funding - BioNTech (Inst)
 
Giuseppe V. Masucci
No Relationships to Disclose
 
Eva Zavadova
No Relationships to Disclose
 
Pam Ohashi
No Relationships to Disclose
 
Michael H. A. Roehrl
No Relationships to Disclose
 
Yutaka Kawakami
Stock and Other Ownership Interests - Bristol-Myers Squibb; Ono Pharmaceutical
Honoraria - Taiho Pharmaceutical
Consulting or Advisory Role - Taiho Pharmaceutical
Research Funding - Asahi Kasei (Inst); Kowa (Inst); R-Tech Ueno (Inst); Sumitomo Dainippon (Inst); Tella, Inc (Inst)
 
Toshihiko Torigoe
Research Funding - Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst)
 
Paolo Antonio Ascierto
Consulting or Advisory Role - Amgen; Array BioPharma; Bristol-Myers Squibb; MSD; Novartis; Roche/Genentech; Ventana Medical Systems
Research Funding - Bristol-Myers Squibb (Inst); Roche/Genentech (Inst); Ventana Medical Systems (Inst)
 
Franco Marincola
No Relationships to Disclose
 
Daniel J. Sargent
Consulting or Advisory Role - Abbvie; Acerta Pharma; ARIAD; Astellas Pharma; AstraZeneca/MedImmune; Biothera; Celldex; Exelixis; Genentech; Incyte; Kyowa Hakko Kirin; Medivation; Merck; Merrimack; Nektar; Novartis; Pharmacyclics; Pique; Spiration; Xbiotech
Research Funding - Celgene (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Celgene
 
Bernard A. Fox
Employment - UbiVac; UbiVac (I)
Leadership - UbiVac
Stock and Other Ownership Interests - UbiVac
Honoraria - Janssen Biotech; Nodality
Consulting or Advisory Role - Dendreon; Janssen Biotech
Research Funding - Aduro Biotech; Bristol-Myers Squibb; DEfiniens; Janssen Biotech; MedImmune (Inst); Perkin Elmer; Ventana Medical Systems; Viralytics
Patents, Royalties, Other Intellectual Property - Patent around the DPV-001 cancer vaccine. This patent is owned by the Providence Health System and licensed to UbiVac
 
Franck Pages
Honoraria - Bristol-Myers Squibb; Roche; Sanofi
Consulting or Advisory Role - Bristol-Myers Squibb; Roche; Sanofi
Speakers' Bureau - Bristol-Myers Squibb; Roche; Sanofi
Research Funding - HalioDx (Inst)
Patents, Royalties, Other Intellectual Property - INSERM